{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"vip-post-surgery","title":"VIP for Post-Surgery Recovery: Evidence-Graded Review","body":"## What's breaking down\n\nPost-surgery involves layers of tissue disruption, inflammation, and immune activation at the surgical site. Incisions or resections create mechanical wounds that trigger repair cascades. If inflammation persists or immune balance shifts, healing slows. Autonomic and neuropeptide signaling can also influence local blood flow and tissue response. VIP is discussed in contexts of immune modulation and autonomic regulation rather than direct symptom masking.\n\n## Why VIP might help you\n\nIf immune or autonomic layers contribute to your post-surgery experience, VIP is studied for pathways tied to tissue responses. One in-vitro study on human bronchial epithelial cells showed VIP accelerated wound closure by promoting cell migration and proliferation via VPAC1 receptors (preclinical). Therefore for you: if local tissue repair processes are relevant after surgery, this points to VIP's association with repair signaling instead of pain suppression. Animal models of intestinal injury after irradiation found VIP reduced inflammatory markers like TNF-alpha and supported epithelial regeneration through secretory cell differentiation (preclinical). Therefore for you: if post-operative gut or barrier integrity plays a role, VIP is examined for those regeneration-related effects. A human cell migration assay indicated faster wound bed repopulation with VIP (preclinical). Therefore for you: if wound margin advancement matters in your recovery, the compound's studied effects align with that layer.\n\n## How these fit together\n\nSingle-compound focus. VIP targets the immune/autonomic layer noted in the peptide chain. No multi-peptide stack applies here.\n\n## What the evidence actually shows\n\nHuman data remain limited. One RNA-Seq analysis of 15 CIRS patients receiving VIP nasal spray reported shifts in metabolic and innate immune gene expression coinciding with symptom changes (human, small n). A randomized trial of aviptadil (VIP analog) in critical COVID-19 respiratory failure showed survival and respiratory recovery differences versus standard care (human). No large randomized controlled trials specifically examine VIP for general post-surgical wound healing or recovery. Preclinical work includes a 2006 study where VIP sped recovery of mechanically wounded human bronchial epithelial cells in culture and increased E-cadherin expression (preclinical). A 2024 mouse irradiation model demonstrated VIP mitigated intestinal damage, lowered TNF-alpha, and promoted Lyz1+ cell expansion (preclinical). An earlier bronchial epithelium wound-healing assay confirmed accelerated area closure blocked by VPAC1 antagonist (preclinical). Arthritis mouse models showed reduced incidence and severity with VIP (preclinical). Evidence inventory: 2 small human transcriptomic or trial reports; multiple animal and cell-culture studies; no large human post-surgery RCTs identified.\n\n## What scientists say\n\nResearchers note VIP's potential in modulating inflammation and supporting epithelial repair in specific injury models. The bronchial cell studies conclude protective effects mediated partly by VPAC1. The irradiation study highlights promotion of secretory differentiation for regeneration. Broader reviews position VIP as an immunomodulator, but emphasize need for targeted clinical validation beyond current contexts like CIRS or acute respiratory failure.\n\n## What people say on Reddit\n\nDiscussions of VIP appear mainly in CIRS or mold-related communities, where users describe changes in inflammation, breathing, or energy after nasal spray use. Specific post-surgery threads are scarce; general peptide recovery conversations focus more on compounds like BPC-157 for incisions or soft tissue. Anecdotal reports remain individual and unverified (anecdotal).\n\n## What people say on X\n\nPosts reference VIP in contexts of blood flow, immune balance, gut function, and general recovery support. One user described it as potentially versatile for multiple systems. Mentions in mold or chronic symptom threads note low endogenous VIP levels correlating with fatigue or immune issues. No detailed post-operative case reports surfaced in recent searches (anecdotal).\n\n## What we do not know\n\nDirect human evidence for VIP accelerating surgical incision healing, reducing post-op scar formation, or shortening recovery timelines is absent. Optimal timing, delivery method, or patient selection post-surgery has not been established in controlled trials. Interactions with standard surgical protocols or other recovery factors remain unstudied at scale. Long-term outcomes beyond short-term markers are unknown.\n\n## Safety and limits\n\nVIP has been administered in specific clinical settings such as nasal spray in CIRS cohorts or intravenous analog in ICU trials with reported monitoring of markers. Individual responses vary; any use occurs outside approved indications for post-surgery. Regulatory status, sourcing quality, and suitability for any given surgical recovery are outside the scope of this review. Consult primary medical sources for personal decisions.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-post-surgery/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP accelerated wound area recovery and increased migration/proliferation of human bronchial epithelial cells in vitro, effects blocked by VPAC1 antagonist.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides direct cell-level data on repair processes relevant to wound healing layers post-surgery.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In a mouse abdominal irradiation model, VIP reduced TNF-alpha, mitigated intestinal inflammation and injury scores, and promoted secretory cell expansion.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Demonstrates in vivo regeneration effects in an injury context.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"RNA-Seq in 15 CIRS patients on VIP nasal spray showed shifts in metabolic state and innate immune functions coinciding with healing markers.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Small human transcriptomic data linking VIP to immune modulation.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Aviptadil (VIP analog) in a 60-day RCT for critical COVID-19 respiratory failure was associated with higher survival and respiratory recovery rates versus controls.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Human trial evidence in acute inflammatory respiratory failure context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP effects on post-surgery recovery lack large-scale dedicated RCTs; existing human data are limited to small or non-surgical populations.","section":"What we do not know","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gaps for readers evaluating applicability.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16965837/","title":"Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells","quote":"The results showed that VIP accelerated the recovery of wound area of HBEC. VIP increased the migration and proliferation of HBEC, and these effects were blocked by a VPAC1 receptor antagonist.","summary":"2006 in-vitro study on human bronchial epithelial cell wound healing with VIP.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:23:38.391Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"43f55c6ed049e8e68702dcbaf0bf85385a331b8c065934443abf3fb526573e2f"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39380035/","title":"Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury","quote":"VIP prominently governs intestinal homeostasis by regulating epithelial progenitor cell proliferation and differentiation and promotes intestinal regeneration following acute irradiation injury.","summary":"2024 mouse study on VIP in irradiation-induced gut injury.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:23:38.391Z","link_status":"ok","quote_status":"verified","prev":"43f55c6ed049e8e68702dcbaf0bf85385a331b8c065934443abf3fb526573e2f","hash":"9b3d82ed62ca7557c812dec4274ca7c096082b464449af18c09695beb365f124"},{"id":"s3","type":"other","url":"https://esmed.org/MRA/mra/article/view/862","title":"RNA-Seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal peptide (VIP) shows a shift in metabolic state and innate immune functions that coincide with healing","quote":"This study surveyed 15 patients... who agreed to have their transcriptomes monitored while receiving off label, exogenous VIP nasal spray treatments.","summary":"2016 small human RNA-Seq study in CIRS patients on VIP.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:23:38.391Z","link_status":"ok","quote_status":"unverified","prev":"9b3d82ed62ca7557c812dec4274ca7c096082b464449af18c09695beb365f124","hash":"7161d88c24b7b199433db8c7789a9786889786ada15c995bebcba78a13c128a6"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/36044317/","title":"The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure","quote":"Among the 21 patients treated with aviptadil, 19 survived to day 28, compared with 4 of the 24 individuals in the SOC group (90% vs 17%, respectively; P <.0001).","summary":"RCT of VIP analog in COVID respiratory failure (from secondary reports).","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:23:38.391Z","link_status":"ok","quote_status":"unverified","prev":"7161d88c24b7b199433db8c7789a9786889786ada15c995bebcba78a13c128a6","hash":"db9f4e0b63048666295966f206a81717bdea4334390e7be9ec4886045d3f1858"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:23:40.935Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Post-Surgery Recovery: Evidence-Graded Review","register":"source_ledger","body":"## What's breaking down\n\nPost-surgery involves layers of tissue disruption, inflammation, and immune activation at the surgical site. Incisions or resections create mechanical wounds that trigger repair cascades. If inflammation persists or immune balance shifts, healing slows. Autonomic and neuropeptide signaling can also influence local blood flow and tissue response. VIP is discussed in contexts of immune modulation and autonomic regulation rather than direct symptom masking.\n\n## Why VIP might help you\n\nIf immune or autonomic layers contribute to your post-surgery experience, VIP is studied for pathways tied to tissue responses. One in-vitro study on human bronchial epithelial cells showed VIP accelerated wound closure by promoting cell migration and proliferation via VPAC1 receptors (preclinical). Therefore for you: if local tissue repair processes are relevant after surgery, this points to VIP's association with repair signaling instead of pain suppression. Animal models of intestinal injury after irradiation found VIP reduced inflammatory markers like TNF-alpha and supported epithelial regeneration through secretory cell differentiation (preclinical). Therefore for you: if post-operative gut or barrier integrity plays a role, VIP is examined for those regeneration-related effects. A human cell migration assay indicated faster wound bed repopulation with VIP (preclinical). Therefore for you: if wound margin advancement matters in your recovery, the compound's studied effects align with that layer.\n\n## How these fit together\n\nSingle-compound focus. VIP targets the immune/autonomic layer noted in the peptide chain. No multi-peptide stack applies here.\n\n## What the evidence actually shows\n\nHuman data remain limited. One RNA-Seq analysis of 15 CIRS patients receiving VIP nasal spray reported shifts in metabolic and innate immune gene expression coinciding with symptom changes (human, small n). A randomized trial of aviptadil (VIP analog) in critical COVID-19 respiratory failure showed survival and respiratory recovery differences versus standard care (human). No large randomized controlled trials specifically examine VIP for general post-surgical wound healing or recovery. Preclinical work includes a 2006 study where VIP sped recovery of mechanically wounded human bronchial epithelial cells in culture and increased E-cadherin expression (preclinical). A 2024 mouse irradiation model demonstrated VIP mitigated intestinal damage, lowered TNF-alpha, and promoted Lyz1+ cell expansion (preclinical). An earlier bronchial epithelium wound-healing assay confirmed accelerated area closure blocked by VPAC1 antagonist (preclinical). Arthritis mouse models showed reduced incidence and severity with VIP (preclinical). Evidence inventory: 2 small human transcriptomic or trial reports; multiple animal and cell-culture studies; no large human post-surgery RCTs identified.\n\n## What scientists say\n\nResearchers note VIP's potential in modulating inflammation and supporting epithelial repair in specific injury models. The bronchial cell studies conclude protective effects mediated partly by VPAC1. The irradiation study highlights promotion of secretory differentiation for regeneration. Broader reviews position VIP as an immunomodulator, but emphasize need for targeted clinical validation beyond current contexts like CIRS or acute respiratory failure.\n\n## What people say on Reddit\n\nDiscussions of VIP appear mainly in CIRS or mold-related communities, where users describe changes in inflammation, breathing, or energy after nasal spray use. Specific post-surgery threads are scarce; general peptide recovery conversations focus more on compounds like BPC-157 for incisions or soft tissue. Anecdotal reports remain individual and unverified (anecdotal).\n\n## What people say on X\n\nPosts reference VIP in contexts of blood flow, immune balance, gut function, and general recovery support. One user described it as potentially versatile for multiple systems. Mentions in mold or chronic symptom threads note low endogenous VIP levels correlating with fatigue or immune issues. No detailed post-operative case reports surfaced in recent searches (anecdotal).\n\n## What we do not know\n\nDirect human evidence for VIP accelerating surgical incision healing, reducing post-op scar formation, or shortening recovery timelines is absent. Optimal timing, delivery method, or patient selection post-surgery has not been established in controlled trials. Interactions with standard surgical protocols or other recovery factors remain unstudied at scale. Long-term outcomes beyond short-term markers are unknown.\n\n## Safety and limits\n\nVIP has been administered in specific clinical settings such as nasal spray in CIRS cohorts or intravenous analog in ICU trials with reported monitoring of markers. Individual responses vary; any use occurs outside approved indications for post-surgery. Regulatory status, sourcing quality, and suitability for any given surgical recovery are outside the scope of this review. Consult primary medical sources for personal decisions.","claims":[{"id":"c1","text":"VIP accelerated wound area recovery and increased migration/proliferation of human bronchial epithelial cells in vitro, effects blocked by VPAC1 antagonist.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides direct cell-level data on repair processes relevant to wound healing layers post-surgery.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In a mouse abdominal irradiation model, VIP reduced TNF-alpha, mitigated intestinal inflammation and injury scores, and promoted secretory cell expansion.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Demonstrates in vivo regeneration effects in an injury context.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"RNA-Seq in 15 CIRS patients on VIP nasal spray showed shifts in metabolic state and innate immune functions coinciding with healing markers.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Small human transcriptomic data linking VIP to immune modulation.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Aviptadil (VIP analog) in a 60-day RCT for critical COVID-19 respiratory failure was associated with higher survival and respiratory recovery rates versus controls.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Human trial evidence in acute inflammatory respiratory failure context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP effects on post-surgery recovery lack large-scale dedicated RCTs; existing human data are limited to small or non-surgical populations.","section":"What we do not know","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gaps for readers evaluating applicability.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16965837/","title":"Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells","quote":"The results showed that VIP accelerated the recovery of wound area of HBEC. VIP increased the migration and proliferation of HBEC, and these effects were blocked by a VPAC1 receptor antagonist.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39380035/","title":"Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury","quote":"VIP prominently governs intestinal homeostasis by regulating epithelial progenitor cell proliferation and differentiation and promotes intestinal regeneration following acute irradiation injury.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"other","url":"https://esmed.org/MRA/mra/article/view/862","title":"RNA-Seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal peptide (VIP) shows a shift in metabolic state and innate immune functions that coincide with healing","quote":"This study surveyed 15 patients... who agreed to have their transcriptomes monitored while receiving off label, exogenous VIP nasal spray treatments.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/36044317/","title":"The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure","quote":"Among the 21 patients treated with aviptadil, 19 survived to day 28, compared with 4 of the 24 individuals in the SOC group (90% vs 17%, respectively; P <.0001).","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":30454,"tokens_out":2870,"cost":0.0452425,"prev_hash":"genesis","hash":"52246e5b2a424feb75025d0c55a899facf7e955be9528f874d78d6e2f7b146a0"}],"provenance":[{"ts":"2026-06-29T22:23:40.935Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Post Surgery\nSlug: vip-post-surgery\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\",\"section_headings\":[\"What's breaking down\",\"Why VIP might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weig","response":"{\n  \"slug\": \"vip-post-surgery\",\n  \"title\": \"VIP for Post-Surgery Recovery: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down\\n\\nPost-surgery involves layers of tissue disruption, inflammation, and immune activation at the surgical site. Incisions or resections create mechanical wounds that trigger repair cascades. If inflammation persists or immune balance shifts, healing slows. Autonomic and neuropeptide signaling can also influence local blood flow and tissue response. VIP is discussed in contexts of immune modulation and autonomic regulation rather than direct symptom masking.\\n\\n## Why VIP might help you\\n\\nIf immune or autonomic layers contribute to your post-surgery experience, VIP is studied for pathways tied to tissue responses. One in-vitro study on human bronchial epithelial cells showed VIP accelerated wound closure by promoting cell migration and proliferation via VPAC1 receptors (preclinical). Therefore for you: if local tissue repair processes are relevant after surgery, this points to VIP's association with repair signaling instead of pain suppression. Animal models of intestinal injury after irradiation found VIP reduced inflammatory markers like TNF-alpha and supported epithelial regeneration through secretory cell differentiation (preclinical). Therefore for you: if post-operative gut or barrier integrity plays a role, VIP is examined for those regeneration-related effects. A human cell migration assay indicated faster wound bed repopulation with VIP (preclinical). Therefore for you: if wound margin advancement matters in your recovery, the compound's studied effects align with that layer.\\n\\n## How these fit together\\n\\nSingle-compound focus. VIP targets the immune/autonomic layer noted in the peptide chain. No multi-peptide stack applies here.\\n\\n## What the evidence actually shows\\n\\nHuman data remain limited. One RNA-Seq analysis of 15 CIRS patients receiving VIP nasal spray reported shifts in metabolic and innate immune gene expressi","tokens_in":30454,"tokens_out":2870,"cost":0,"prev":"genesis","hash":"bf8d0d45fa170b47fdc6cbb1be8669676ecbf5ebd0c2a91e23074f2dd0554867"},{"ts":"2026-07-17T02:43:26.420Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-post-surgery","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bf8d0d45fa170b47fdc6cbb1be8669676ecbf5ebd0c2a91e23074f2dd0554867","hash":"04f0024352c0e35a6c59d2f9ef69332183372f1459b5906f8ce12ce2f6449cc7"}],"energy":{"passes":2,"tokens_in":30454,"tokens_out":2870,"tokens_total":33324,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"04f0024352c0e35a6c59d2f9ef69332183372f1459b5906f8ce12ce2f6449cc7"},"posted_at":"2026-06-29T21:33:51.929Z","created_at":"2026-06-29T21:33:51.929Z","updated_at":"2026-07-17T02:43:26.420Z","machine":{"shape":"article.machine/v1","slug":"vip-post-surgery","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-post-surgery","json":"https://miscsubjects.com/api/articles/vip-post-surgery","bundle":"https://miscsubjects.com/api/articles/vip-post-surgery/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-post-surgery/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-post-surgery","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-post-surgery\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-post-surgery\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-post-surgery/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-post-surgery\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-post-surgery | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-post-surgery","json":"/api/articles/vip-post-surgery","markdown":"/api/articles/vip-post-surgery/bundle?format=markdown","skill":"/api/articles/vip-post-surgery/skill","topology":"/api/articles/vip-post-surgery/topology","versions":"/api/articles/vip-post-surgery/revisions","invocations":"/api/articles/vip-post-surgery/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-post-surgery","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"92ac0d91636afe95ebc64914487a837a90eeff71aec7b9829c4b8e2a4ef763d6","object":{"object_type":"article-object","identity":{"id":"article:vip-post-surgery","slug":"vip-post-surgery","title":"VIP for Post-Surgery Recovery: Evidence-Graded Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/vip-post-surgery","role":"explain","audience":"human"},"skill":{"route":"/api/articles/vip-post-surgery/skill","role":"direct behavior","audience":"model","content":"---\nname: vip-post-surgery\ndescription: Apply the VIP for Post-Surgery Recovery: Evidence-Graded Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# VIP for Post-Surgery Recovery: Evidence-Graded Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/vip-post-surgery). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/vip-post-surgery.\n- Read claims and relationships at /api/articles/vip-post-surgery/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Post-surgery involves layers of tissue disruption, inflammation, and immune activation at the surgical site. Incisions or resections create mechanical wounds that trigger repair cascades. If inflammation persists or imm\n\n## Representations\n\n- Human: /a/vip-post-surgery\n- JSON: /api/articles/vip-post-surgery\n- Relationships: /api/articles/vip-post-surgery/topology\n- History: /api/articles/vip-post-surgery/revisions\n"},"json":{"route":"/api/articles/vip-post-surgery","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/vip-post-surgery/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","vip","post","surgery"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/vip-post-surgery/invocations?status=success","failure_events":"/api/articles/vip-post-surgery/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"vip-post-surgery","title":"VIP for Post-Surgery Recovery: Evidence-Graded Review","body":"## What's breaking down\n\nPost-surgery involves layers of tissue disruption, inflammation, and immune activation at the surgical site. Incisions or resections create mechanical wounds that trigger repair cascades. If inflammation persists or immune balance shifts, healing slows. Autonomic and neuropeptide signaling can also influence local blood flow and tissue response. VIP is discussed in contexts of immune modulation and autonomic regulation rather than direct symptom masking.\n\n## Why VIP might help you\n\nIf immune or autonomic layers contribute to your post-surgery experience, VIP is studied for pathways tied to tissue responses. One in-vitro study on human bronchial epithelial cells showed VIP accelerated wound closure by promoting cell migration and proliferation via VPAC1 receptors (preclinical). Therefore for you: if local tissue repair processes are relevant after surgery, this points to VIP's association with repair signaling instead of pain suppression. Animal models of intestinal injury after irradiation found VIP reduced inflammatory markers like TNF-alpha and supported epithelial regeneration through secretory cell differentiation (preclinical). Therefore for you: if post-operative gut or barrier integrity plays a role, VIP is examined for those regeneration-related effects. A human cell migration assay indicated faster wound bed repopulation with VIP (preclinical). Therefore for you: if wound margin advancement matters in your recovery, the compound's studied effects align with that layer.\n\n## How these fit together\n\nSingle-compound focus. VIP targets the immune/autonomic layer noted in the peptide chain. No multi-peptide stack applies here.\n\n## What the evidence actually shows\n\nHuman data remain limited. One RNA-Seq analysis of 15 CIRS patients receiving VIP nasal spray reported shifts in metabolic and innate immune gene expression coinciding with symptom changes (human, small n). A randomized trial of aviptadil (VIP analog) in critical COVID-19 respiratory failure showed survival and respiratory recovery differences versus standard care (human). No large randomized controlled trials specifically examine VIP for general post-surgical wound healing or recovery. Preclinical work includes a 2006 study where VIP sped recovery of mechanically wounded human bronchial epithelial cells in culture and increased E-cadherin expression (preclinical). A 2024 mouse irradiation model demonstrated VIP mitigated intestinal damage, lowered TNF-alpha, and promoted Lyz1+ cell expansion (preclinical). An earlier bronchial epithelium wound-healing assay confirmed accelerated area closure blocked by VPAC1 antagonist (preclinical). Arthritis mouse models showed reduced incidence and severity with VIP (preclinical). Evidence inventory: 2 small human transcriptomic or trial reports; multiple animal and cell-culture studies; no large human post-surgery RCTs identified.\n\n## What scientists say\n\nResearchers note VIP's potential in modulating inflammation and supporting epithelial repair in specific injury models. The bronchial cell studies conclude protective effects mediated partly by VPAC1. The irradiation study highlights promotion of secretory differentiation for regeneration. Broader reviews position VIP as an immunomodulator, but emphasize need for targeted clinical validation beyond current contexts like CIRS or acute respiratory failure.\n\n## What people say on Reddit\n\nDiscussions of VIP appear mainly in CIRS or mold-related communities, where users describe changes in inflammation, breathing, or energy after nasal spray use. Specific post-surgery threads are scarce; general peptide recovery conversations focus more on compounds like BPC-157 for incisions or soft tissue. Anecdotal reports remain individual and unverified (anecdotal).\n\n## What people say on X\n\nPosts reference VIP in contexts of blood flow, immune balance, gut function, and general recovery support. One user described it as potentially versatile for multiple systems. Mentions in mold or chronic symptom threads note low endogenous VIP levels correlating with fatigue or immune issues. No detailed post-operative case reports surfaced in recent searches (anecdotal).\n\n## What we do not know\n\nDirect human evidence for VIP accelerating surgical incision healing, reducing post-op scar formation, or shortening recovery timelines is absent. Optimal timing, delivery method, or patient selection post-surgery has not been established in controlled trials. Interactions with standard surgical protocols or other recovery factors remain unstudied at scale. Long-term outcomes beyond short-term markers are unknown.\n\n## Safety and limits\n\nVIP has been administered in specific clinical settings such as nasal spray in CIRS cohorts or intravenous analog in ICU trials with reported monitoring of markers. Individual responses vary; any use occurs outside approved indications for post-surgery. Regulatory status, sourcing quality, and suitability for any given surgical recovery are outside the scope of this review. Consult primary medical sources for personal decisions.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-post-surgery/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP accelerated wound area recovery and increased migration/proliferation of human bronchial epithelial cells in vitro, effects blocked by VPAC1 antagonist.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides direct cell-level data on repair processes relevant to wound healing layers post-surgery.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In a mouse abdominal irradiation model, VIP reduced TNF-alpha, mitigated intestinal inflammation and injury scores, and promoted secretory cell expansion.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Demonstrates in vivo regeneration effects in an injury context.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"RNA-Seq in 15 CIRS patients on VIP nasal spray showed shifts in metabolic state and innate immune functions coinciding with healing markers.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Small human transcriptomic data linking VIP to immune modulation.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Aviptadil (VIP analog) in a 60-day RCT for critical COVID-19 respiratory failure was associated with higher survival and respiratory recovery rates versus controls.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Human trial evidence in acute inflammatory respiratory failure context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP effects on post-surgery recovery lack large-scale dedicated RCTs; existing human data are limited to small or non-surgical populations.","section":"What we do not know","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gaps for readers evaluating applicability.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16965837/","title":"Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells","quote":"The results showed that VIP accelerated the recovery of wound area of HBEC. VIP increased the migration and proliferation of HBEC, and these effects were blocked by a VPAC1 receptor antagonist.","summary":"2006 in-vitro study on human bronchial epithelial cell wound healing with VIP.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:23:38.391Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"43f55c6ed049e8e68702dcbaf0bf85385a331b8c065934443abf3fb526573e2f"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39380035/","title":"Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury","quote":"VIP prominently governs intestinal homeostasis by regulating epithelial progenitor cell proliferation and differentiation and promotes intestinal regeneration following acute irradiation injury.","summary":"2024 mouse study on VIP in irradiation-induced gut injury.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:23:38.391Z","link_status":"ok","quote_status":"verified","prev":"43f55c6ed049e8e68702dcbaf0bf85385a331b8c065934443abf3fb526573e2f","hash":"9b3d82ed62ca7557c812dec4274ca7c096082b464449af18c09695beb365f124"},{"id":"s3","type":"other","url":"https://esmed.org/MRA/mra/article/view/862","title":"RNA-Seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal peptide (VIP) shows a shift in metabolic state and innate immune functions that coincide with healing","quote":"This study surveyed 15 patients... who agreed to have their transcriptomes monitored while receiving off label, exogenous VIP nasal spray treatments.","summary":"2016 small human RNA-Seq study in CIRS patients on VIP.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:23:38.391Z","link_status":"ok","quote_status":"unverified","prev":"9b3d82ed62ca7557c812dec4274ca7c096082b464449af18c09695beb365f124","hash":"7161d88c24b7b199433db8c7789a9786889786ada15c995bebcba78a13c128a6"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/36044317/","title":"The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure","quote":"Among the 21 patients treated with aviptadil, 19 survived to day 28, compared with 4 of the 24 individuals in the SOC group (90% vs 17%, respectively; P <.0001).","summary":"RCT of VIP analog in COVID respiratory failure (from secondary reports).","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:23:38.391Z","link_status":"ok","quote_status":"unverified","prev":"7161d88c24b7b199433db8c7789a9786889786ada15c995bebcba78a13c128a6","hash":"db9f4e0b63048666295966f206a81717bdea4334390e7be9ec4886045d3f1858"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:23:40.935Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Post-Surgery Recovery: Evidence-Graded Review","register":"source_ledger","body":"## What's breaking down\n\nPost-surgery involves layers of tissue disruption, inflammation, and immune activation at the surgical site. Incisions or resections create mechanical wounds that trigger repair cascades. If inflammation persists or immune balance shifts, healing slows. Autonomic and neuropeptide signaling can also influence local blood flow and tissue response. VIP is discussed in contexts of immune modulation and autonomic regulation rather than direct symptom masking.\n\n## Why VIP might help you\n\nIf immune or autonomic layers contribute to your post-surgery experience, VIP is studied for pathways tied to tissue responses. One in-vitro study on human bronchial epithelial cells showed VIP accelerated wound closure by promoting cell migration and proliferation via VPAC1 receptors (preclinical). Therefore for you: if local tissue repair processes are relevant after surgery, this points to VIP's association with repair signaling instead of pain suppression. Animal models of intestinal injury after irradiation found VIP reduced inflammatory markers like TNF-alpha and supported epithelial regeneration through secretory cell differentiation (preclinical). Therefore for you: if post-operative gut or barrier integrity plays a role, VIP is examined for those regeneration-related effects. A human cell migration assay indicated faster wound bed repopulation with VIP (preclinical). Therefore for you: if wound margin advancement matters in your recovery, the compound's studied effects align with that layer.\n\n## How these fit together\n\nSingle-compound focus. VIP targets the immune/autonomic layer noted in the peptide chain. No multi-peptide stack applies here.\n\n## What the evidence actually shows\n\nHuman data remain limited. One RNA-Seq analysis of 15 CIRS patients receiving VIP nasal spray reported shifts in metabolic and innate immune gene expression coinciding with symptom changes (human, small n). A randomized trial of aviptadil (VIP analog) in critical COVID-19 respiratory failure showed survival and respiratory recovery differences versus standard care (human). No large randomized controlled trials specifically examine VIP for general post-surgical wound healing or recovery. Preclinical work includes a 2006 study where VIP sped recovery of mechanically wounded human bronchial epithelial cells in culture and increased E-cadherin expression (preclinical). A 2024 mouse irradiation model demonstrated VIP mitigated intestinal damage, lowered TNF-alpha, and promoted Lyz1+ cell expansion (preclinical). An earlier bronchial epithelium wound-healing assay confirmed accelerated area closure blocked by VPAC1 antagonist (preclinical). Arthritis mouse models showed reduced incidence and severity with VIP (preclinical). Evidence inventory: 2 small human transcriptomic or trial reports; multiple animal and cell-culture studies; no large human post-surgery RCTs identified.\n\n## What scientists say\n\nResearchers note VIP's potential in modulating inflammation and supporting epithelial repair in specific injury models. The bronchial cell studies conclude protective effects mediated partly by VPAC1. The irradiation study highlights promotion of secretory differentiation for regeneration. Broader reviews position VIP as an immunomodulator, but emphasize need for targeted clinical validation beyond current contexts like CIRS or acute respiratory failure.\n\n## What people say on Reddit\n\nDiscussions of VIP appear mainly in CIRS or mold-related communities, where users describe changes in inflammation, breathing, or energy after nasal spray use. Specific post-surgery threads are scarce; general peptide recovery conversations focus more on compounds like BPC-157 for incisions or soft tissue. Anecdotal reports remain individual and unverified (anecdotal).\n\n## What people say on X\n\nPosts reference VIP in contexts of blood flow, immune balance, gut function, and general recovery support. One user described it as potentially versatile for multiple systems. Mentions in mold or chronic symptom threads note low endogenous VIP levels correlating with fatigue or immune issues. No detailed post-operative case reports surfaced in recent searches (anecdotal).\n\n## What we do not know\n\nDirect human evidence for VIP accelerating surgical incision healing, reducing post-op scar formation, or shortening recovery timelines is absent. Optimal timing, delivery method, or patient selection post-surgery has not been established in controlled trials. Interactions with standard surgical protocols or other recovery factors remain unstudied at scale. Long-term outcomes beyond short-term markers are unknown.\n\n## Safety and limits\n\nVIP has been administered in specific clinical settings such as nasal spray in CIRS cohorts or intravenous analog in ICU trials with reported monitoring of markers. Individual responses vary; any use occurs outside approved indications for post-surgery. Regulatory status, sourcing quality, and suitability for any given surgical recovery are outside the scope of this review. Consult primary medical sources for personal decisions.","claims":[{"id":"c1","text":"VIP accelerated wound area recovery and increased migration/proliferation of human bronchial epithelial cells in vitro, effects blocked by VPAC1 antagonist.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides direct cell-level data on repair processes relevant to wound healing layers post-surgery.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In a mouse abdominal irradiation model, VIP reduced TNF-alpha, mitigated intestinal inflammation and injury scores, and promoted secretory cell expansion.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Demonstrates in vivo regeneration effects in an injury context.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"RNA-Seq in 15 CIRS patients on VIP nasal spray showed shifts in metabolic state and innate immune functions coinciding with healing markers.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Small human transcriptomic data linking VIP to immune modulation.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Aviptadil (VIP analog) in a 60-day RCT for critical COVID-19 respiratory failure was associated with higher survival and respiratory recovery rates versus controls.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Human trial evidence in acute inflammatory respiratory failure context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP effects on post-surgery recovery lack large-scale dedicated RCTs; existing human data are limited to small or non-surgical populations.","section":"What we do not know","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gaps for readers evaluating applicability.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:23:40.087Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16965837/","title":"Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells","quote":"The results showed that VIP accelerated the recovery of wound area of HBEC. VIP increased the migration and proliferation of HBEC, and these effects were blocked by a VPAC1 receptor antagonist.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39380035/","title":"Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury","quote":"VIP prominently governs intestinal homeostasis by regulating epithelial progenitor cell proliferation and differentiation and promotes intestinal regeneration following acute irradiation injury.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"other","url":"https://esmed.org/MRA/mra/article/view/862","title":"RNA-Seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal peptide (VIP) shows a shift in metabolic state and innate immune functions that coincide with healing","quote":"This study surveyed 15 patients... who agreed to have their transcriptomes monitored while receiving off label, exogenous VIP nasal spray treatments.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/36044317/","title":"The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure","quote":"Among the 21 patients treated with aviptadil, 19 survived to day 28, compared with 4 of the 24 individuals in the SOC group (90% vs 17%, respectively; P <.0001).","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":30454,"tokens_out":2870,"cost":0.0452425,"prev_hash":"genesis","hash":"52246e5b2a424feb75025d0c55a899facf7e955be9528f874d78d6e2f7b146a0"}],"provenance":[{"ts":"2026-06-29T22:23:40.935Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Post Surgery\nSlug: vip-post-surgery\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\",\"section_headings\":[\"What's breaking down\",\"Why VIP might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weig","response":"{\n  \"slug\": \"vip-post-surgery\",\n  \"title\": \"VIP for Post-Surgery Recovery: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down\\n\\nPost-surgery involves layers of tissue disruption, inflammation, and immune activation at the surgical site. Incisions or resections create mechanical wounds that trigger repair cascades. If inflammation persists or immune balance shifts, healing slows. Autonomic and neuropeptide signaling can also influence local blood flow and tissue response. VIP is discussed in contexts of immune modulation and autonomic regulation rather than direct symptom masking.\\n\\n## Why VIP might help you\\n\\nIf immune or autonomic layers contribute to your post-surgery experience, VIP is studied for pathways tied to tissue responses. One in-vitro study on human bronchial epithelial cells showed VIP accelerated wound closure by promoting cell migration and proliferation via VPAC1 receptors (preclinical). Therefore for you: if local tissue repair processes are relevant after surgery, this points to VIP's association with repair signaling instead of pain suppression. Animal models of intestinal injury after irradiation found VIP reduced inflammatory markers like TNF-alpha and supported epithelial regeneration through secretory cell differentiation (preclinical). Therefore for you: if post-operative gut or barrier integrity plays a role, VIP is examined for those regeneration-related effects. A human cell migration assay indicated faster wound bed repopulation with VIP (preclinical). Therefore for you: if wound margin advancement matters in your recovery, the compound's studied effects align with that layer.\\n\\n## How these fit together\\n\\nSingle-compound focus. VIP targets the immune/autonomic layer noted in the peptide chain. No multi-peptide stack applies here.\\n\\n## What the evidence actually shows\\n\\nHuman data remain limited. One RNA-Seq analysis of 15 CIRS patients receiving VIP nasal spray reported shifts in metabolic and innate immune gene expressi","tokens_in":30454,"tokens_out":2870,"cost":0,"prev":"genesis","hash":"bf8d0d45fa170b47fdc6cbb1be8669676ecbf5ebd0c2a91e23074f2dd0554867"},{"ts":"2026-07-17T02:43:26.420Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-post-surgery","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bf8d0d45fa170b47fdc6cbb1be8669676ecbf5ebd0c2a91e23074f2dd0554867","hash":"04f0024352c0e35a6c59d2f9ef69332183372f1459b5906f8ce12ce2f6449cc7"}],"energy":{"passes":2,"tokens_in":30454,"tokens_out":2870,"tokens_total":33324,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"04f0024352c0e35a6c59d2f9ef69332183372f1459b5906f8ce12ce2f6449cc7"},"posted_at":"2026-06-29T21:33:51.929Z","created_at":"2026-06-29T21:33:51.929Z","updated_at":"2026-07-17T02:43:26.420Z","machine":{"shape":"article.machine/v1","slug":"vip-post-surgery","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-post-surgery","json":"https://miscsubjects.com/api/articles/vip-post-surgery","bundle":"https://miscsubjects.com/api/articles/vip-post-surgery/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-post-surgery/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-post-surgery","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-post-surgery\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-post-surgery\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-post-surgery/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-post-surgery\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-post-surgery | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-post-surgery","json":"/api/articles/vip-post-surgery","markdown":"/api/articles/vip-post-surgery/bundle?format=markdown","skill":"/api/articles/vip-post-surgery/skill","topology":"/api/articles/vip-post-surgery/topology","versions":"/api/articles/vip-post-surgery/revisions","invocations":"/api/articles/vip-post-surgery/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-post-surgery","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"92ac0d91636afe95ebc64914487a837a90eeff71aec7b9829c4b8e2a4ef763d6"}}}